In a report released today, Steve Scala from TD Cowen maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

The AstraZeneca share price is down almost 20% since September! What’s behind this drop, and where do analysts think the ...

AstraZeneca (AZN) and Merck (MRK) reported positive long-term survival data for their drug Lynparza in the treatment of ...

AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results ...

Updated results from the OlympiA Phase 3 trial showed AstraZeneca (AZN) and Merck’s (MRK) Lynparza demonstrated sustained, clinically ...

Shares of AstraZeneca PLC AZN slid 1.78% to £105.12 Tuesday, on what proved to be an all-around dismal trading session for ...

Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...

GlobalData’s analysts predict $158 million in global sales for AZD0486 by 2030, with $2.4 billion for Epkinly and $949 ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

AstraZeneca and Daiichi Sankyo have shared the data they believe can secure approval for datopotamab deruxtecan (Dato-DXd) at ...

AstraZeneca is proud to announce the successful conclusion of its inaugural Week of Service, which took place across the ...

During the Week of Service, staff members from countries including Cameroon, Ivory Coast, Senegal, Ghana, Kenya, and South ...